Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib in advanced neuroendocrine tumors
NCT02267967Phase 1Completed
- Sponsor
- Hutchison MediPharma (HMP)
- Start
- Oct 2014
- Primary completion
- Aug 2017
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of surufatinib in neuroendocrine tumors (NETs), sponsored by Hutchison MediPharma (HMP). Primary endpoint: Incidence and severity of Adverse Events and Serious Adverse Events. Started Oct 2014; status: completed.
02
Drugs
surufatinib
03
Conditions
neuroendocrine tumors (NETs)
Beyond the preview
Go deeper on NCT02267967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02267967.